New hope for advanced lung cancer patients in Head-to-Head drug trial
NCT ID NCT06564324
Summary
This study compares two targeted drugs for advanced lung cancer with a specific genetic change called ROS1. About 138 patients who haven't tried this type of treatment will receive either the experimental drug taletrectinib or the standard drug crizotinib. Researchers want to see which drug better controls cancer growth and extends the time before the disease worsens.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, Shangdong, China
Contact
-
Chongqing University Cancer Hospital
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, China
Contact
-
Guangxi Medical University Cancer Hospital
RECRUITINGNanning, Guangxi, China
Contact
Contact
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, China
Contact
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, China
Contact
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, China
Contact
-
Linyi Cancer Hospital
NOT_YET_RECRUITINGLinyi, Shandong, China
Contact
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Shanxi Cancer Hospital
NOT_YET_RECRUITINGTaiyuan, Shanxi, China
Contact
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
NOT_YET_RECRUITINGHangzhou, Zhejiang, China
Contact
-
The First Affiliated Hospital of Anhui Medical University
NOT_YET_RECRUITINGHefei, Anhui, China
Contact
-
The First Affiliated Hospital of Guangdong Pharmaceutical University
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
Contact
-
The First Affiliated Hospital of Guangzhou Medical University
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
Contact
-
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITINGNanchang, Jiangxi, China
Contact
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, China
Contact
-
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXi’an, Shanxi, China
Contact
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, China
Contact
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China
Contact
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, China
Contact
-
The Fourth Hospital of Hebei Medical University
NOT_YET_RECRUITINGShijiazhuang, Hebei, China
Contact
-
Tianjin Cancer Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, China
Contact
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact
-
West China Hospital of Sichuan University
NOT_YET_RECRUITINGChengdu, Sichuan, China
Contact
-
Yunnan Cancer Hospital
NOT_YET_RECRUITINGKunming, Yunnan, China
Contact
-
Zhejiang Cancer Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, China
Contact
-
Zhongshan Hospital, Fudan University
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.